Beta-3 Agonist and Anti-muscarinic Agent for Sjogren’s Syndrome With Overactive Bladder
Condition(s):Sjogren’s Syndrome; Overactive Bladder SyndromeLast Updated:August 10, 2021Unknown status
Hide Studies Not Open or Pending
Condition(s):Sjogren’s Syndrome; Overactive Bladder SyndromeLast Updated:August 10, 2021Unknown status
Condition(s):Sjogren’s SyndromeLast Updated:May 25, 2022Not yet recruiting
Condition(s):ANCA Associated Vasculitis; Sjogren’s SyndromeLast Updated:September 14, 2021Completed
Condition(s):Primary Sjögren’s SyndromeLast Updated:September 8, 2021Unknown status
Condition(s):Sjögren SyndromeLast Updated:October 31, 2022Recruiting
Condition(s):Sjogren’s Syndrome; Interstitial Lung Disease; Primary Pulmonary Lymphoma (Disorder); Chronic Bronchiolitis; Bronchiectasis; Lung Diseases; Cystic Lung Disease; Lymphocytic Interst. PneumonitisLast Updated:October 27, 2022Suspended
Condition(s):Systemic Lupus Erythematosus; Sjogren’s Syndrome; Inflammatory Myositis; Psoriatic Arthritis; Gout; Ankylosing Spondylitis; Arthritis of Multiple Sites Associated With Inflammatory Bowel Disease (Diagnosis); OsteoarthritisLast Updated:June 3, 2022Terminated
Condition(s):Dry Eye; Dry Eye Syndromes; Sjogren’s SyndromeLast Updated:February 10, 2023Recruiting
Condition(s):Primary Sjögren SyndromeLast Updated:July 19, 2021Unknown status
Condition(s):Dry Eye Disease; Sjögren SyndromeLast Updated:February 20, 2024Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.